On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox ...

Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

Today's health news includes what RFK Jr. can do on vaccines, escaped monkeys, and who know in the Make America Healthy Again ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

British health officials say they have identified four cases of the new, more infectious version of mpox that first emerged ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...

Vaccines that prevent smallpox and mpox come in two varieties. One uses a single shot of a live virus but carries the risk of ...

Private insurance companies in the U.S. aren’t required to cover the cost of the mpox vaccine, which costs $270 a dose.

Democratic Republic of Congo has been unable to launch an mpox vaccination campaign in the capital Kinshasa due to a shortage ...